2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Small Cell Lung Carcinoma
2
Radiation Injuries
2
Leukemia, Myeloid, Acute
2
Congenital Abnormalities
2
Brain Neoplasms
2
Wilms Tumor
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Sezary Syndrome
1
Recurrence
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Neurotoxicity Syndromes
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Mycosis Fungoides
1
Multiple Myeloma
1
Memory Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Neutrophilic, Chronic
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelomonocytic, Acute
1
Interventions
Rituximab
226
Cyclophosphamide
202
fludarabine phosphate
108
Peripheral Blood Stem Cell Transplantation
103
Filgrastim
87
Etoposide
76
Cytarabine
70
ibrutinib
68
Mycophenolic Acid
67
Bortezomib
66
Whole-Body Irradiation
63
Cyclosporine
63
Melphalan
59
Lenalidomide
59
Bendamustine Hydrochloride
58
Vincristine
53
Radiotherapy
53
fludarabine
52
Tacrolimus
50
Doxorubicin
48
Busulfan
48
Methotrexate
47
Antilymphocyte Serum
42
Prednisone
41
Carmustine
40
Dexamethasone
38
Granulocyte Colony-Stimulating Factor
33
venetoclax
31
acalabrutinib
31
zanubrutinib
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Mantle-Cell
×
Lithium
×
Clear all
NCT00408681
2017-03-07
GVHD
Fred Hutchinson Cancer Center
Phase NA
Completed
20 enrolled
27 charts